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Abstract
Background: The efficacy of a non-prescription drug to support weight loss programs has yet to be compared.
This clinical trial investigates the comparability of orlistat 60 milligram (mg) and polyglucosamine.
Methods: Sixty-four overweight or obese subjects were included in a two-center double-blind study. One center
was in Germany [center 1] and the other was in Italy [center 2].
The subjects (26 in center 1 and 38 in center 2) were recommended to follow a calorie deficit of about 2000 kilojoules/day
and to increase their physical activity to 3 metabolic equivalent hours (MET h)/day. In both centers, subjects were
randomized to receive polyglucosamine (2 tablets x 2) or orlistat (1 capsule x 3) for a period of 12 weeks. Weight loss was
considered as a main variable together with the reduction of 5 per cent (%) of body weight (5R). Body Mass Index (BMI)
and waist circumference (WC) were taken as secondary variables.
Results: A significant difference in weight loss between the two groups was shown, 6.7 ± 3.14 kilogram (kg) in group
polyglucosamine versus 4.8 ± 2.24 kg in group orlistat (t test p< 0.05) respectively; BMI and WC reduction were also more
consistent with polyglucosamine treatment than with orlistat treatment (t test p< 0.05). No significant difference was found
in the number of subjects who achieved 5R (70% for polyglucosamine and 55% for orlistat group; chi square p > 0.05).
The administration of polyglucosamine following energy restriction and increase in physical activity reduces body
weight, BMI and WC more efficiently than orlistat
Conclusions: Even though both groups were instructed to adopt a calorie restricted diet together with increased
physical activity an additional weight loss in the polyglucosamine group of 1.6 kilogram (kg) compared to the orlistat
group (6.2 ± 3.46 versus 4.6 ± 2.36 kg) in both centers was seen despite the higher consumption of carbohydrates in
Italy (center 2). A typical Italian diet is usually high in carbohydrate content whereas Germans tend to consume meals
with higher fat content. This leads to the assumption that polyglucosamine limits both fat and carbohydrate
absorption which would explain the comparable effective weight reduction in the Italian participants.
Trial registration: Trial registration at ClinicalTrials.gov NCT02529631, registered on Aug 19, 2015 retrospectively
registered.
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Background
Overweight and obesity are major public health chal-
lenges of the 21st century in the European region
[1] and guidelines to assist practitioners and patients
for an appropriate treatment have been compiled by
many professional societies for nutrition [2]. Thera-
pists often recommend the use of weight loss aids
such as orlistat to obtain a more rapid weight loss
due to the ability of this product to inhibit the pan-
creatic lipase and the dietary triglycerides bioavail-
ability [3].
The withdrawal of registered weight loss products
from the market has led therapists to look for cur-
rently available treatment options. One product that
is also used to help support body weight management
is polyglucosamine, a low molecular weight chitosan
(LMWC) that binds fats, creating an emulsion that
[4] makes them non-bioavailable. The emulsion can
be partially eliminated or used by colonic bacteria as
a fuel due to their ability to hydrolize LMWC with
the bacterial enzyme chitosanase [5, 6].
For both products to obtain a reduction in body
weight of about 5% in a relatively short period of time
(2 to 4 months), a daily caloric restriction combined
with increased physical activity is recommended.
There are currently no studies comparing the two prod-
ucts and there exist no published data in the literature.
The aim of this study was to compare their effectiveness
in a double blind clinical trial in two different centers.
Methods
Trial design
The trial was a randomized, double-blind study in two
centers comparing the treatment effects of orlistat and
polyglucosamine and conducted in accordance with the
European Medical Device Directive 92/43/EEC, European
harmonized Standard (EN) International Standardization
Organisation (ISO) 14155-1, the Declaration of Helsinki
and the National Data Protection Act. The centers
involved in the study were: center 1, the Diabetological
center in Dreieich-Sprendlingen, Germany, center 2, the
Monitoring Food and Diseases (MAP) in Rende (Cosenza,
Italy).
Participants
Sixty four subject were admitted (26 in center 1 and 38
in center 2) as shown in Fig. 1.
Patient recruitment and development during the ran-
domized double-blind clinical investigation comparing
polyglucosamine and orlistat.
The admission criteria were overweight subjects with a
BMI ≥ 28 kilogram/square-meter (kg/m2) and < 45 kg/
m2; waist circumference of more than 80 centimeter
(cm) for women and greater than 94 cm for men; age 21
to 70 years.
The energy intake was also an important admission
criterion. The kilojoule (kJ) intake was measured using
a questionnaire based on weekly servings [7] and those
subjects reporting an energy intake lower than the stand-
ard value calculated according to Miffin St-Jeor Equation
(based upon weight, height, age) [8] were excluded from
the clinical trial.
Other exclusion criteria were as follows: pregnancy or
breast-feeding, addiction to alcohol, inability to fulfill the
requirements of the trial protocol, cancer, malignant
tumor, hypersensitivity reactions to crustaceans or any
of the ingredients of the two products. Patients with
Fig. 1 CONSORT Statement Flow Chart
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chronic disease not brought under control with an ap-
propriate therapy or with diabetes were excluded.
All patients were informed in detail about the pur-
pose of the clinical trial both orally and in writing and
their written consent obtained. Insurance to cover the
participants, at a level appropriate to the risks posed by
the clinical trial was provided and complied with the
principles of the latest version of the Declaration of
Helsinki (October 2008).
All patients were given the same instructions regarding
dietary changes based on the requirements outlined in a
nutrition course manual, which includes a list of foods
to be avoided (or reduced) in order to achieve 2000 kJ/day
deficit (about 500 kilocalories (kcal)). Those foods high in
energy density such as processed meat (sausages, salami
etc.), meat, cheese, butter, oil, pasta, beer, wine / alcohol,
sweet beverages were particularly cautioned against
overconsumption.
All patients were taught how to increase physical ac-
tivity level at intensity equivalent to 3 METs/day and
given a fitness digital versatile disk (DVD) featuring an
exercise program to help motivate them to continue
doing exercises on their own. The recommendation of
expending 3 METs/day corresponds to 21 METs/week
(about 1 hour/day of moderate intensity exercise) and
was based upon the cut-off to prevent weight gain while
consuming a usual diet [9].
The energy expenditure of 3 METs corresponds ap-
proximately to 45 minutes (min) of walking or 15 min of
biking at 15 kilometer per hour (km/h), or 15 min of
swimming [10].
Variables
The primary target variable was the body weight,
whereas the other anthropometric measures (BMI and
waist circumference) were considered secondary vari-
ables only.
The cutoff reduction of 5% of body weight (5R) was
also taken as a primary goal.
The plasma lipids and blood pressure were also mea-
sured but they were not considered as variables because
patients under therapy with antihypertensive drugs and/
or statins were also admitted to the trial.
All the measurements were taken at the moment of
the enrolment (Visit 1/T1) and at least four times during
the therapy: at baseline, after 4, 8 and 12 weeks of
treatment.
Investigational medical device and comparator
Orlistat 60 mg (1 capsule x 3) was filled in blue cap-
sules and polyglucosamine (2 tablets x 2) was avail-
able as compressed pale colored tablets. However,
there was a difference in the dosing regimens: 3 x 1
capsule (a capsule three times daily with each meal)
and 2 x 2 tablets (two tablets twice a day with a
meal).
Push-through blisters, each containing 3 x 1 blue
capsules and 3 x 2 ivory colored tablets were given
to both treatment groups. Therefore, these patients
were each given 2 tablets and a capsule three times
a day.
All participants received the same number of tablets
and capsules (see Table 1).
Double Dummy Design blister pack
Thirty-two blister packs each providing one-day sup-
ply (6 tablets + 3 capsules) were given to study subjects
so that every four weeks they had to return to the
center for a new supply. The subjects were requested to
attend the follow-up visits by phone calls (see Fig. 2).
Sample size
A sample size of 40 patients in each group had a suffi-
ciently high probability (Cohen's effect size 0.5, 5%
significance level, 80% power and 20% drop out) of de-
tecting a statistically significant difference by means of
the t-test. The sample was not stratified by gender. For
the random process, block randomization was used with
a block of size four.
Compliance
Measurement of medication adherence was obtained by
counting the number of residual tablets. The compliance
was fixed to a consumption of at least 44 blisters during
the study period (48 blisters were given and 46 should
have been consumed). The physical activity and the cal-
oric restriction were not taken as a compliance measure.
Statistical methods
The metric data were characterized according to their
statistical parameters, mean value, standard deviation
and extrema. The differences between the groups were
calculated by means of the t-test (probability (p)-value
pt) under the assumption that the variances were the
same. The correlation coefficient (r) was calculated
Table 1 Treatment scheme; double blind placebo/
polyglucosamine/orlistat
Either
Breakfast 2 placebo tablets 1 placebo capsule
Lunch 2 polyglucosamine tablets 1 placebo capsule
Dinner 2 polyglucosamine tablets 1 placebo capsule
Or
Breakfast 2 placebo tablets 1 orlistat 60 mg capsule
Lunch 2 placebo tablets 1 orlistat 60 mg capsule
Dinner 2 placebo tablets 1 orlistat 60 mg capsule
In the group treated with polyglucosamine, two tablets, also called placebo
tablets (provided for breakfast) contained no active substance
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between the initial body weight and the body weight
reduction.
For the evaluation of the primary endpoints, the re-
sults of the intention to treat analysis (ITT) were com-
pared to those of per-protocol population (PP). For the
analysis of subjects reaching 5R the Chi2-test was used.
The biometric analysis was performed using the statis-
tical software package SPSS®, Version 19.0 and Microsoft
Excel® was used to add new data records to a list and
create a graphic illustration of the results.
Results
According to the randomisation list 32 subjects (50%)
were assigned to the polyglucosamine treatment and an-
other 32 subjects (50%) were allocated to the orlistat
treatment.
Fifty-eight subjects concluded the trial, 27 in the poly-
glucosamine group and 31 in the orlistat group, respect-
ively. In the ITT population, 6 patients were excluded
from the analysis of the PP population.
-Four subjects reported side effects: 3 in the polyglu-
cosamine group (meteorism, constipation and vomiting)
and one in the orlistat group (diarrhea):
Group polyglucosamine:
Patient No. 7 (discontinued after visit 8) because of
meteorism
Patient No. 12 (discontinued after visit 4) because of
constipation
Patient No. 14 (discontinued after visit 4) because of
nausea and vomiting
Group orlistat:
Patient No. 34 (discontinued after visit 2) because of
diarrhoea.
Two subjects of the polyglucosamine group were ex-
cluded because the compliance was lower than 95%
(about 75% and 80%, respectively), whereas all the sub-
jects in the orlistat group were compliant.
The complaints given as the reason for the termin-
ation in group polyglucosamine were symptoms such as
stomach ache and bloating, nausea and vomiting as well
as constipation, palpitations and mood swings. Medical
treatment was not sought for these complaints as they
were only temporary and without any further conse-
quences. As a result of stress and an irregular lifestyle
including occasional diarrhoea, discontinuation of the
treatment in the orlistat group took place after the
second visit, as requested by the patients. All the
other recorded adverse events/reactions were mild
and transient and medical attention was not required.












Fig. 2 Double Dummy Design blister pack
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frequency in both treatment groups. The symptoms
were consistent with those specified in the respective
patient information leaflet. The occurrence of serious
adverse events (SAE) was not observed in both
regimens.
The anthropometric measurements recorded at base-
line were similar in both groups (see Table 2).
There were no significant changes in blood pressure,
pulse rate and laboratory findings between the two treat-
ment groups (data not reported). Hence, both treatment
methods can be considered to be comparable in efficacy
for these last variables.
The average modifications of the anthropometric vari-
ables are reported in Tables 3, 4, 5 and 6.
Table 3 Anthropometric measurements (PP) at different control times (T1 baseline and, T5, T9, T13) in groups treated with
polyglucosamine and orlistat
Variable Group T1a T4a T9a T13a
Weight (kg) polyglucosamine 100.9 ± 13.44 97.2 ± 12.61 95.4 ± 12.79 94.1 ± 13.41
orlistat 97.9 ± 11.55 95.1 ± 11.24 94.5 ± 11.98 93.1 ± 11.82
BMI (kg/m2) polyglucosamine 34.6 ± 3.69 33.4 ± 3.58 32.8 ± 3.50 32.3 ± 3.59
orlistat 34.7 ± 4.76 33.7 ± 4.60 33.4 ± 4.68 33.0 ± 4.63
WC (cm) polyglucosamine 113.4 ± 11.13 109.6 ± 12.10 107.4 ± 11.85 105.1 ± 11.98
orlistat 109.5 ± 10.13 106.8 ± 9.55 104.2 ± 9.30 103.4 ± 9.14
aThe differences between groups are not statistically significant (t test)
Table 5 Anthropometric measurements (ITT) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG
and O
Variable Group T1a T4a T9a T13a
Weight (kg) polyglucosamine 100.6 ± 13.22 97.2 ± 12.37 95.6 ± 12.54 94.3 ± 13.06
orlisat 98.2 ± 11.47 95.5 ± 11.25 94.9 ± 11.99 93.6 ± 11.88
BMI (kg/m2) polyglucosamine 34.6 ± 3.70 33.5 ± 3.62 32.9 ± 3.61 32.5 ± 3.69
orlistat 34.8 ± 4.73 33.8 ± 4.60 33.6 ± 4.69 33.1 ± 4.66
WC (cm) polyglucosamine 112.4 ± 10.95 109.2 ± 11.46 107.4 ± 11.25 105.1 ± 11.21
orlistat 110.0 ± 10.38 107.4 ± 9.98 104.8 ± 9.93 104.1 ± 9.84
aThe differences between groups are not statistically significant (t test)
Table 4 Anthropometric measurements (PP) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG and O
Variable Group T1 T1 - T5 T1 - T9 T1 - T13
Weight (kg) polyglucosamine 100.9 ± 13.44 3.71 ± 2.67 5.49 ± 2.63# 6.74 ± 3.14#
orlistat 97.9 ± 11.55 2.82 ± 1.42 3.43 ± 1.69 4.78 ± 2.24
BMI (kg/m2) polyglucosamine 34.6 ± 3.69 1.26 ± 0.88 1.89 ± 0.90# 2.33 ± 1.09*
orlistat 34.7 ± 4.76 1.00 ± 0.54 1.23 ± 0.64 1.71 ± 0.86
WC (cm) polyglucosamine 113.4 ± 11.13 3.81 ± 3.11 5.96 ± 4.13 8.33 ± 4.42*
orlistat 109.5 ± 10.13 2.61 ± 2.65 5.29 ± 2.47 6.10 ± 3.43
#p<0.01, * p < 0.05
Table 2 Anthropometric measures at baseline (ITT: number (N) = 64) in groups to be treated with polyglucosamine and orlistat
Variable Total Group polyglucosamine Group orlistat pa/b
N 64 32 32
Gender (male/female) 28/36 16/16 12/20 P = 0.313a
Age (years) 50.0 ± 9.17 50.0 ± 9.10 50.1 ± 9.38 P = 0.989b
Weight (kg) 99.4 ± 12.33 100.6 ± 13.22 98.2 ± 11.47 P = 0.446b
Height (m) 169.3 ± 8.09 170.3 ± 7.60 168.4 ± 8.58 P = 0.358b
BMI (kg/m2) 34.7 ± 4.21 34.6 ± 3.70 34.8 ± 4.73 P = 0.896b
WC (cm) 111.2 ± 10.66 112.4 ± 10.95 110.0 ± 10.38 P = 0.358b
aChi square test; bt test
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At visit (T)1, the average value of the body weight in
the polyglucosamine group was higher than in the orli-
stat group (3.0 kg), but the difference was not statisti-
cally significant (t test; p > 0.05).
During the 12-week period, there was a reduction
in all the anthropometric variables for both treatment
groups (Table 3). However, the reduction of all the
variables (Table 7) was significantly more consistent
in the group treated with polyglucosamine.
The average body weight reduction within the 12-
week period (T13-T1) for PG was significantly higher for
both the ITT and PP analyses (see Figs. 3, 4 and 5).
The reduction of BMI was -2.3 ± 1.09 kg/m2 in the
group polyglucosamine and -1.7 ± 0.86 kg/m2 in the group
orlistat; the WC modification was also more pronounced
following the polyglucosamine treatment than with orli-
stat, -8.3 ± 4.42 cm and -6.1 ± 3.43 cm, respectively.
The differences were statistically significant (t test
p < 0.05) both for ITT and PP analyses, with the only
exception for WC in the ITT analysis where the dif-
ference between the two groups turned out not to be
statistically significant (t test p = 0.179).
The number of subjects that reached 5R was not dif-
ferent in the two groups (Table 7) even though after
treatment, there was an increase in percentage for both
the ITT and PP analyses (see Table 7).
There was no significant correlation between weight
reduction and weight at baseline (r = 0.101 in the ITT
Table 6 Anthropometric measurements (ITT) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG
and O
Variable Group T1 T1 - T5 T1 - T9 T1 - T13
Weight (kg) polyglucosamine 100.6 ± 13.22 3.36 ± 2.66 4.98 ± 2.90# 6.24 ± 3.46*
orlistat 98.2 ± 11.47 2.73 ± 1.48 3.32 ± 1.77 4.63 ± 2.36
BMI (kg/m2) polyglucosamine 34.6 ± 3.70 1.13 ± 0.88 1.71 ± 0.99* 2.15 ± 1.21
orlistat 34.8 ± 4.73 0.97 ± 0.54 1.20 ± 0.67 1.66 ± 0.90
WC (cm) polyglucosamine 112.4 ± 10.95 3.22 ± 3.29 5.06 ± 4.56 7.34 ± 4.83
orlistat 110.0 ± 10.38 2.53 ± 2.65 5.12 ± 2.60 5.91 ± 3.54
#p <0.01, *p < 0.05
Table 7 Body weight decrease following the treatment with polyglucosamine and orlistat
Decrease in body weight [kg] N Average ± standard-deviation(SD) Mini- mum Maxi- mum Cut off 5% decrease [N] Cut off 5% decrease [%]
Total (PP) 58 5.7 ± 2.85 0.3 13.0 36 62.1
Group polyglucosamine 27 6.7 ± 3.14 0.3 13.0 19 70.4
Group orlistat 31 4.8 ± 2.24 1.5 11.9 17 54.8
P t value 0.008 Chi square p > 0.05
Total (ITT) 64 5.4 ± 3.05 -0.9 13.0 37 57.8
Group polyglucosamine 32 6.2 ± 3.46 -0.9 13.0 21 65.6
Group orlistat 32 4.6 ± 2.36 0.0 11.9 16 50.0
Pt value 0.033 Chi square p > 0.05
Fig. 3 ITT percentage of 5-%- Responder, is the percentage of
subjects with a body weight reduction of at least 5% compared
to baseline
Fig. 4 PP percentage of 5-%-Responder, is the percentage of
subjects with a body weight reduction of at least 5% compared
to baseline
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and r = 0.104 in the PP). However, BMI measurements
obtained in center 1 were more favorable (1.46 versus
1.40 in center 1, 2.14 versus 1.13 in center 2). Gender
did not affect the results.
The data mentioned below are the general outcomes
using repeated measures ANOVA. In fact, if the curves
of the changes do not intersect with each other, a signifi-
cant outcome during the course can be expected when
there are significant differences across time points.
Therefore, we can conclude that the results are valid.
PP: Taking into account weight loss over time dur-
ing the four visits V1, V5, V9 and V13, the factor
time (F-test: 157.3; ptime < 0.001) as well as the group
differences over time (F-test: 6.2; ptime x group = 0.002)
show a statistically significance (see Table 8).
ITT: Taking into account weight loss over time during
the four visits V1, V5, V9 and V13, the factor time (F-
test: 139.5; ptime <0.001) as well as the group differ-
ences over time (F-test: 4.2; ptime x group= 0.017) show
a statistical difference (see Tables 9 and 10).
Fig. 5 Comparison of the mean body weight in kg
Table 8 Weight loss over time in the PP group
Body weight PP Sum of squares (Type III) Degree of freedom df F-test p-value
Factor Time 1054.662 3 157.285 <0.001
Time x Group 41.360 3 6.167 0.002
Error 375.551 168 - -
Table 9 Weight loss over time in the ITT group
Body weight ITT Sum of squares (Type III) df F-test p-value
Factor Time 1033.924 3 139.545 <0.001
Time x Group 31.234 3 4.216 0.017
Error 459.374 186 - -
Table 10 Results of the separate analysis of the data reported
Parameter Factor Time Time x Group
F-test p-value F-test p-value
Body weight (PP) 157.285 <0.001 6.167 0.002
Body weight (ITT) 139.545 <0.001 4.216 0.017
BMI (PP) 153.830 <0.001 5.027 0.007
BMI (ITT) 136.927 <0.001 3.306 0.041
Waist circumference (PP) 125.351 <0.001 2.831 0.059
Waist circumference (ITT) 105.392 <0.001 1.568 0.213
The p-values were determined using the Greenhouse-Geisser correction
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The results obtained from the separate analysis of data
reported in center 1 (Germany) and center 2 (Italy) were
slightly different.
In center 1, the two products ended up with simi-
lar body weight reduction in the PP analysis (-4.9 ±
4.18 kg for polyglucosamine and -5.3 ± 3.03 kg for
orlistat, respectively); in center 2, the body weight
reduction was more consistent for polyglucosamine
than for orlistat (-7.8 ± 1.73 kg and -4.5 ± 1.58 kg,
respectively).
The development of weight loss in the two groups is
shown in Fig. 5.
The red solid line shows the reduction in body weight
(kg) of the orlistat 60 mg group (PP). The red dashed
line shows the reduction in body (kg) weight of the orli-
stat 60mg group (ITT). The turquoise solid line shows
the reduction in body weight (kg) of the polyglucosa-
mine group (PP). The turquoise dashed line shows the
reduction in body weight (kg) of the polyglucosamine
group (ITT).
Discussion
The purpose of this clinical trial was to conduct a direct
comparison between two treatments, orlistat and poly-
glucosamine as a treatment option for body weight
management.
Orlistat is used worldwide in obese and overweight
subjects and is one of the most commonly used weight
loss medications in Europe for weight management ac-
cording to the labelling text approved by the European
Medicines Agency [11].
There are some clinical studies with orlistat at 60 mg
and 120 mg against placebo [3, 12–14] in subjects
undergoing caloric restriction for a period of treatment
ranging between 14 and 104 weeks. These trials show
that in general, an approximate weight reduction of
about 2 kg can be added to weight loss induced by cal-
oric restriction alone.
There are also studies on polyglucosamine reporting a
similar or an even higher weight reduction [4, 15] in
subjects following caloric restriction and treated for a
period of time ranking between 12 and 24 weeks.
A recent study found that in a large number of cases
(115 subjects comparing polyglucosamine versus Pla-
cebo) the consumption of polyglucosamine plus energy
restriction of about 2000 kJ combined with an increase
in physical activity level to 7 METs/week for 24 weeks
induced a reduction of 4.5 kg [16].
In the present study, the intensity of physical activity
was increased to 21 METs/week and the body weight
reduction was more evident despite a shorter period of
treatment. Following this schedule, the mean weight loss
in both regimens, regardless of gender and the initial
body weight, was a reduction of more than 4 kg body
weight in 12 weeks. These results confirm the import-
ance of adding more physical activity to any type of
pharmacological treatments.
Similar recommendations for diet and physical exer-
cise are part of the current guidelines of international
societies for nutrition, obesity, and diabetes.
However, a particular aspect has to be considered in
relation to the more consistent effect shown in center 2.
This center is located in South of Italy where the
carbohydrate consumption, in terms of bread and pasta,
is more common than in Germany.
Pasta in particular has to be addressed, because in
Italy its consumption is about 80 gram/day/person.
An “average” dish of pasta consists of at least 1500 kJ
and the intake of most of the overweight pasta con-
sumers frequently exceeds 2500 kJ / portion [17].
Despite the different ingredients used to prepare a
dish of pasta (oil, cheese, meat etc.), the energy con-
tent is mainly due to carbohydrates (75-80%) than to
fats and proteins. This implies that a limitation of the
energy intake of 2000 kJ/day in the subjects enrolled
in center 2 was derived mainly from carbohydrates
[18–20], whereas in center 1 (Germany) the caloric
restriction was mainly derived from a reduction in
dietary fat (sausages, meat, butter).
In other terms, the energy intake restriction was iden-
tical in the two centers but the type of food to be
avoided was not identical.
The bioavailability of fats is reduced by both poly-
glucosamine (fat emulsion effect) and by orlistat
(lipase inhibition). However, from experimental data
on polyglucosamine an increase of glucose in faeces
was found [6] also indicating a reduction of carbohy-
drate availability. This last aspect has been shown
indirectly during the therapy of metabolic syndrome,
where the polyglucosamine treatment was found to
reduce blood glucose levels as well [4].
In theory, whereas orlistat limits the fat bioavailability,
polyglucosamine seems to limit both fat and carbohy-
drate absorption and this difference gives a reasonable
explanation for the similar effective weight reduction in
a diet with carbohydrates as the main energy source.
Conclusion
In conclusion, there are indications that the more evi-
dent effect of polyglucosamine compared to orlistat on
the anthropometric variables could be determined by
the quality of energy limitation (carbohydrates/fats).
Although more data should be provided in this area
to confirm our observations, the results of the current
trial give an insight to the different outcomes that can
be obtained with the same product in different coun-
tries characterized by different food cultures.
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